AstraZeneca
AstraZeneca plc is a British–Swedish multinational pharmaceutical and biopharmaceutical company. The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. It is a constituent of the FTSE 100 Index and has secondary listings on Nasdaq OMX Stockholm, Nasdaq New York, the Bombay Stock Exchange and on the National Stock Exchange of India.
About AstraZeneca in brief
AstraZeneca plc is a British–Swedish multinational pharmaceutical and biopharmaceutical company. The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, respiratory and inflammation. It has its research and development concentrated in three strategic centres: Cambridge, England; Gothenburg, Sweden and Gaithersburg in Maryland, U.S. It is a constituent of the FTSE 100 Index and has secondary listings on Nasdaq OMX Stockholm, Nasdaq New York, the Bombay Stock Exchange and on the National Stock Exchange of India. In March 2013 Astra Zeneca announced a major corporate restructuring, including the closure of its research and development activities in the UK and at Lund, Sweden. It also announced that it would focus on three therapeutic areas: Respiratory Inflammation, Autoimmunity & Respiration, and Drug Discovery & Development. In April 2012, AstaZeneca and Amgen announced a collaboration on treatments for inflammatory diseases. In June 2012, the company announced a two-stage deal for the joint acquisition of the biotechnology company Amylin Pharmaceuticals. It was agreed that Bristol Myers Squibb would acquire Amyl in for USD 5.3 billion in cash and the assumption of USD 1.7 billion in debt, with Astra Zeneca then paying USD 3.
4 bn in cash to Bristol Myers Squibb. In July 2012, it announced it would cut an additional 2,300 jobs, including 1,600 jobs in Cambridge and 1,300 in Lund. In February 2013, it said it would move its corporate headquarters from London to Cambridge in 2016. The announcement included the announcement that the company would cut 1, 600 jobs, which included the announcement that it would move its corporate headquarters from London to Cambridge in 2016. In October 2013, Astra announced that it would focus on traditional chemical drugs, for research on traditional pharmaceuticals. In January 2014, it announced that it would focus on traditional chemical drugs for research and development in Sweden and Möndal in Sweden. In December 2014, the company announced that It would focus on traditional chemical drugs for research & development in Sweden, for research and for drug development in the United States. In May 2015, Ast Zen announced that it would focus on traditional chemical drug research and development in the United S.A. and the United Korea. In November 2014, AstraZen announced that it would focus on traditional chemical drugs for research&development in the U.S., including Spirogen and Definiens. In January 2015, the company announced the closing of its Research and Development activities at R&D facility in Aley Park in Chesoughborough, UK.
You want to know more about AstraZeneca?
This page is based on the article AstraZeneca published in Wikipedia (as of Feb. 08, 2021) and was automatically summarized using artificial intelligence.
